POXEL (OTCMKTS:PXXLF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.
According to Zacks, “Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company’s product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France. “
OTCMKTS:PXXLF opened at $8.11 on Friday. POXEL has a twelve month low of $8.11 and a twelve month high of $8.11.
COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Downgrades POXEL (PXXLF) to Hold” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/zacks-investment-research-downgrades-poxel-pxxlf-to-hold.html.
Get a free copy of the Zacks research report on POXEL (PXXLF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for POXEL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POXEL and related companies with MarketBeat.com's FREE daily email newsletter.